|Table of Contents|

Research progress of tumor organoids and their application in drug resistance research

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 11
Page:
2124-2128
Research Field:
Publishing date:

Info

Title:
Research progress of tumor organoids and their application in drug resistance research
Author(s):
QI Wu; YE Shihui; LIN Junqiang; LIN Liang; WU Xia; LIN Feilong; KE Hao; ZHAO Limin
Human Aging Research Institute(HARI) and School of Life Science,Nanchang University,Jiangxi Nanchang 330031,China.
Keywords:
organoid; technical improvements; tumor; drug resistance
PACS:
R730
DOI:
10.3969/j.issn.1672-4992.2023.11.028
Abstract:
Organoid,as a three-dimensional structure micro organ that has been rapidly developed since its birth and widely used in various experimental platforms,compared with traditional experimental models such as 2D cells and patient derived xenografts(PDX),it has more complex structures and multiple cell morphologies similar to real organs,and can more closely match the physiological functions of the source tissues or organs.In addition,with the innovation and improvement of organ like culture technology and analysis means in research,the establishment of increasingly rich culture medium schemes and high-throughput screening methods makes the application of organ like organisms more complete and diversified.At the same time,the emerging organ like technology plays an important role in tumor research,especially in drug screening,disease modeling and other fields,which can be used as highly reliable experimental models.This review summarizes some improvements and refinements in culture and analysis methods of tumor like organs in recent years,as well as the advantages of tumor like organs compared with traditional experimental models in development and application,and finally summarizes the research progress of tumor like organs in drug resistance application.The overview of drug resistance in tumor like organs in this paper will be helpful to provide a more reliable theoretical basis and methodological reference for the study of tumor drug resistance.

References:

[1]KRATOCHVIL MJ,SEYMOUR AJ,LI TL,et al.Engineered materials for organoid systems［J］.Nat Rev Mater,2019,4(9):606-622.
[2]LANGHANS SA.Three-dimensional in vitro cell culture models in drug discovery and drug repositioning［J］.Front Pharmacol,2018,9:6.
[3]DING S,HSU C,WANG Z,et al.Patient-derived micro-organospheres enable clinical precision oncology［J］.Cell Stem Cell,2022,29(6):905-917.e906.
[4]TUVESON D,CLEVERS H.Cancer modeling meets human organoid technology［J］.Science,2019,364(6444):952-955.
[5]GRANAT LM,KAMBHAMPATI O,KLOSEK S,et al.The promises and challenges of patient-derived tumor organoids in drug development and precision oncology［J］.Animal Model Exp Med,2019,2(3):150-161.
[6]LAU HCH,KRANENBURG O,XIAO H,et al.Organoid models of gastrointestinal cancers in basic and translational research［J］.Nat Rev Gastroenterol Hepatol,2020,17(4):203-222.
[7]REZAKHANI S,GJOREVSKI N,LUTOLF MP.Extracellular matrix requirements for gastrointestinal organoid cultures［J］.Biomaterials,2021,276:121020.
[8]KAUR S,KAUR I,RAWAL P,et al.Non-matrigel scaffolds for organoid cultures［J］.Cancer Lett,2021,504:58-66.
[9]HEO JH,KANG D,SEO SJ,et al.Engineering the extracellular matrix for organoid culture［J］.Int J Stem Cells,2022,15(1):60-69.
[10]KOZLOWSKI MT,CROOK CJ,KU HT.Towards organoid culture without matrigel［J］.Commun Biol,2021,4(1):1387.
[11]KIM S,MIN S,CHOI YS,et al.Tissue extracellular matrix hydrogels as alternatives to Matrigel for culturing gastrointestinal organoids［J］.Nat Commun,2022,13(1):1692.
[12]FANG G,LU H,RODRIGUEZ DE LA FUENTE L,et al.Mammary tumor organoid culture in non-adhesive alginate for luminal mechanics and high-throughput drug screening［J］.Adv Sci(Weinh),2021,8(21):e2102418.
[13]GJOREVSKI N,SACHS N,MANFRIN A,et al.Designer matrices for intestinal stem cell and organoid culture［J］.Nature,2016,539(7630):560-564.
[14]CRUZ-ACUNA R,QUIROS M,HUANG S,et al.PEG-4MAL hydrogels for human organoid generation,culture,and in vivo delivery［J］.Nat Protoc,2018,13(9):2102-2119.
[15]NORKIN M,ORDONEZ-MORAN P,HUELSKEN J.High-content,targeted RNA-seq screening in organoids for drug discovery in colorectal cancer［J］.Cell Rep,2021,35(3):109026.
[16]KONG J,LEE H,KIM D,et al.Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients［J］.Nat Commun,2020,11(1):5485.
[17]WU Y,LI K,LI Y,et al.Grouped-seq for integrated phenotypic and transcriptomic screening of patient-derived tumor organoids［J］.Nucleic Acids Res,2022,50(5):e28.
[18]ZHAO N,POWELL RT,YUAN X,et al.Morphological screening of mesenchymal mammary tumor organoids to identify drugs that reverse epithelial-mesenchymal transition［J］.Nat Commun,2021,12(1):4262.
[19]FONG EL,TOH TB,LIN QX,et al.Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer［J］.Biomaterials,2018,159:229-240.
[20]LEE SH,HU W,MATULAY JT,et al.Tumor evolution and drug response in patient-derived organoid models of bladder cancer［J］.Cell,2018,173(2):515-528.e517.
[21]NUCIFORO S,FOFANA I,MATTER MS,et al.Organoid models of human liver cancers derived from tumor needle biopsies［J］.Cell Rep,2018,24(5):1363-1376.
[22]KIM M,MUN H,SUNG CO,et al.Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening［J］.Nat Commun,2019,10(1):3991.
[23]BORETTO M,MAENHOUDT N,LUO X,et al.Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening［J］.Nat Cell Biol,2019,21(8):1041-1051.
[24]SHI R,RADULOVICH N,NG C,et al.Organoid cultures as preclinical models of non-small cell lung cancer［J］.Clin Cancer Res,2020,26(5):1162-1174.
[25]SACHS N,PAPASPYROPOULOS A,ZOMER-VAN OMMEN DD,et al.Long-term expanding human airway organoids for disease modeling［J］.Embo J,2019,38(4):e100300.
[26]KALAMARA A,TOBALINA L,SAEZ-RODRIGUEZ J.How to find the right drug for each patient? Advances and challenges in pharmacogenomics［J］.Curr Opin Syst Biol,2018,10:53-62.
[27]GAO D,VELA I,SBONER A,et al.Organoid cultures derived from patients with advanced prostate cancer［J］.Cell,2014,159(1):176-187.
[28]DUARTE AA,GOGOLA E,SACHS N,et al.BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance［J］.Nat Methods,2018,15(2):134-140.
[29]TAKEBE T,WELLS JM.Organoids by design［J］.Science,2019,364(6444):956-959.
[30]NUSSINOV R,TSAI CJ,JANG H.Anticancer drug resistance:An update and perspective［J］.Drug Resist Updat,2021,59:100796.
[31]XIAN L,ZHAO P,CHEN X,et al.Heterogeneity,inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer［J］.Cell Oncol(Dordr),2022,45(5):1019-1036.
[32]NAJAFI M,MORTEZAEE K,MAJIDPOOR J.Cancer stem cell(CSC) resistance drivers［J］.Life Sci,2019,234:116781.
[33]HUANG EH,WICHA MS.Colon cancer stem cells:implications for prevention and therapy［J］.Trends Mol Med,2008,14(11):503-509.
[34]USUI T,SAKURAI M,UMATA K,et al.Hedgehog signals mediate anti-cancer drug resistance in three-dimensional primary colorectal cancer organoid culture［J］.Int J Mol Sci,2018,19(4):1098.
[35]UKAI S,HONMA R,SAKAMOTO N,et al.Molecular biological analysis of 5-FU-resistant gastric cancer organoids,KHDRBS3 contributes to the attainment of features of cancer stem cell［J］.Oncogene,2020,39(50):7265-7278.
[36]HAN T,GOSWAMI S,HU Y,et al.Lineage reversion drives WNT independence in intestinal cancer［J］.Cancer Discov,2020,10(10):1590-1609.
[37]ZHAO Y,LI ZX,ZHU YJ,et al.Single-cell transcriptome analysis uncovers intratumoral heterogeneity and underlying mechanisms for drug resistance in hepatobiliary tumor organoids［J］.Adv Sci(Weinh),2021,8(11):e2003897.
[38]SAORIN G,CALIGIURI I,RIZZOLIO F.Microfluidic organoids-on-a-chip:The future of human models［J］.Semin Cell Dev Biol,2023,144:41-54.
[39]KIM SK,KIM YH,PARK S,et al.Organoid engineering with microfluidics and biomaterials for liver,lung disease,and cancer modeling［J］.Acta Biomater,2021,132:37-51.
[40]SCHUSTER B,JUNKIN M,KASHAF SS,et al.Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids［J］.Nat Commun,2020,11(1):5271.
[41]CRUZ-ACUA R,QUIRS M,FARKAS AE,et al.Synthetic hydrogels for human intestinal organoid generation and colonic wound repair［J］.Nat Cell Biol,2017,19(11):1326-1335.
[42]BROGUIERE N,ISENMANN L,HIRT C,et al.Growth of epithelial organoids in a defined hydrogel［J］.Adv Mater,2018,30(43):e1801621.
[43]CAPELING MM,CZERWINSKI M,HUANG S,et al.Nonadhesive alginate hydrogels support growth of pluripotent stem cell-derived intestinal organoids［J］.Stem Cell Reports,2019,12(2):381-394.
[44]XIA X,LI F,HE J,et al.Organoid technology in cancer precision medicine［J］.Cancer Lett,2019,457:20-27.
[45]ARTEGIANI B,HENDRIKS D,BEUMER J,et al.Fast and efficient generation of knock-in human organoids using homology-independent CRISPR-Cas9 precision genome editing［J］.Nat Cell Biol,2020,22(3):321-331.
[46]LESAVAGE BL,SUHAR RA,BROGUIERE N,et al.Next-generation cancer organoids［J］.Nat Mater,2022,21(2):143-159.
[47]KRETZSCHMAR K.Cancer research using organoid technology［J］.J Mol Med(Berl),2021,99(4):501-515.

Memo

Memo:
National Natural Science Foundation of China（No.82260488，32200679，81902714）;国家自然科学基金（编号：82260488，32200679，81902714）；中国博士后科学基金（编号：2021TQ0137，2021M701544）；云南省应用基础研究重点项目（编号：202001AT070102，202001AT070104）；重庆市自然科学基金（编号：CSTB2022NSCQ-MSX056）；江西省研究生创新专项资金项目（编号：YC
Last Update: 2023-04-28